Image guided needle placement
DeviceStereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
NCT Number: NCT02991352
Treatment of vascular malformations requires the placement of a needle within anatomically non well defined, pathological vessels, which may be as small as 1 mm, with the current state of the art relying exclusively on two dimensional fluoroscopy images for guidance. The investigators hypothesize that the combination of stereotactic image guidance with existing targeting methods will result in faster and more reproducible needle placements.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
ARTORG Center for Biomedical Engineering, Bern, Switzerland
This prospective study aims to investigate the feasibility of the utilization of stereotactic image guidance technology for the needle based percutaneous treatment of peripheral vascular malformations. The specific device to be utilized is the CAS-One IR system, CE marked for use with needle based procedures in combination with medical image data including MRI data, as required by this study.
Utilizing feedback from the stereotactic image guidance system, the interventionalist will attempt to place the needle within the malformation. The position and orientation of the needle relative to the anatomy will be displayed on 2D slices from the MRI, as well as relative to a 3D volume rendering of the patient anatomy constructed from MRI data. The position of the needle relative to the desired position within the malformation will be evaluated utilizing fluoroscopy.
If necessary the position of the needle will be adjusted, this adjustment can be performed utilizing navigated feedback or standard fluoroscopy feedback at the discretion of the physician. The final position of the needle will be confirmed on intra-operative DSA imaging and the sclerosant will be applied according to standard clinical protocols.
This single-centre pilot study will involve a total of 10 patients suffering from peripheral vascular malformations. Only non-emergency adult patients will be considered for inclusion in this trial. Inclusion will be at the discretion of the treating physician and patient. As the study is designed as a pilot trial, no comparator is considered and no blinding performed. The trial will be performed over a period of nine months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
Time frame: During the intervention (duration approx. 90 minutes on average)
Time from start of targeting to alcohol embolization in minutes
Time frame: During the intervention (duration approx. 90 minutes on average)
Measured by the C-arm imaging device in seconds
Time frame: During the intervention (duration approx. 90 minutes on average)
Measured by the C-arm imaging device in μGym²
Time frame: During the intervention (duration approx. 90 minutes on average)
Measured by the nurses in milliliter
Time frame: During the intervention (duration approx. 90 minutes on average)
Defined as number of skin punctures, counted by the investigator
Time frame: During the intervention (duration approx. 90 minutes on average)
Asked by the investigator
Time frame: Directly after the intervention (60 minutes afterwards at the latest)
Filled out by the interventionalist
Insel Gruppe AG, University Hospital Bern
Other
Acronym: SIGVaM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07728825
Cardiovascular Abnormalities, Cardiovascular Diseases
Fallujah, Al-Anbar Governorate, Iraq
View Trial DetailsNCT05563831
Angiomatosis, CLOVES Syndrome
Paris, France
View Trial DetailsNCT03972592
Cardiovascular Abnormalities, Cardiovascular Diseases
Angers, France
View Trial DetailsNCT02384122
Anemia, Angiodysplasia
Apeldoorn, Gelderland, Netherlands
View Trial Details